Ipsen Global - A Biopharmaceutical Company | Innovation for Patient Care

WHO WE ARE

As a mid-sized global biopharmaceutical company, Ipsen improves patients’ lives through research, innovation and the development of transformative medicines in Oncology, Rare Disease and Neuroscience.

WHAT WE DO

WHAT WE DO

Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to patients.

Author Image

Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs. We’re leveraging the full force of Ipsen’s infrastructure, innovation and passion to develop new therapies and valuable collaborations.

David Loew

CEO

PATIENTS

Putting patients at the heart of our work

Our commitment to improving the lives and medical outcomes of patients is the driving force behind every decision made at Ipsen. We believe in working with patients, for patients, listening to their needs and involving their insights in the entire.

SUSTAINABILITY

SUSTAINABILITY

Shaping a more sustainable future

At Ipsen, our shared purpose drives us to create a healthier, more resilient future for people and the planet. Through our sustainability framework, Generation Ipsen, we are redefining what it means to lead responsibly, with a bold commitment to protecting the environment, advancing patient care, and empowering our people and communities.

Careers at Ipsen

Ipsen offers a multitude of exciting opportunities for talented and motivated people in careers ranging from medial and clinical research to sales, marketing, finance, IT, HR and legal services. We are committed to providing our employees with a workplace that is welcoming, challenging and inclusive.

Discover trending stories

28 October 2024 2 mins read

Science-First Collaborations: Ipsen’s Blueprint to External Innovation

David Jenkins, SVP and Head of External Innovation and Research, leads efforts to identify, evaluate and secure new programs across Ipsen’s three strategic areas of Oncology, Rare disease, and Neuroscience. He shares his insights on the essential role that collaboration,…

25 October 2024 2 mins read

Ipsen is now a great place to work in 28 countries: A New Milestone in our culture journey

Ipsen is proud to announce that 12 countries have been certified as a Great Place to Work in 2024. With that we are now considered as employer of choice in a total of 28 countries worldwide. This significant achievement reflects…

24 October 2024 2 mins read

Building a Sustainable Future: Ipsen’s Journey with the United Nations Global Compact 

The United Nations Global Compact is a voluntary initiative that calls on CEOs worldwide to implement universal sustainability principles and support the United Nations (UN) goals. By joining the UN Global Compact, companies commit to aligning their strategies and operations with ten fundamental pri

17 October 2024 0 mins read

Financial results for the first nine months of 2024

The financial results for the first half of the year will be published on July 25, 2024 at 7H00 and a conference call will take place at 13H00 CET.

14 October 2024 2 mins read

Excellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes

Meeting the world’s highest standard for operational excellence is rare, and it’s even rarer to do it twice. Ipsen’s manufacturing site in Signes first received the Gold Shingo Prize for operational excellence in 2020.

11 October 2024 1 mins read

Sustainability in the Supply Chain: Ipsen’s First Supplier Sustainability Day 

Sustainability plays a critical role in shaping the future of our business and the world at large. To ensure we embed sustainability in our supply chain, we recently hosted our inaugural Supplier Sustainability Day event, bringing in key partners to meet with Ipsen leaders.  

04 October 2024 2 mins read

Looking after a loved one with Progressive Familial Intrahepatic Cholestasis: Francesca’s Story

A few months after Eva Luna was born, her mother Francesca realised something wasn’t quite right. Within the span of a few days, their world was turned upside down when her daughter was diagnosed with a rare liver disease, known as Progressive Familial Intrahepatic Cholestasis (PFIC). Yet despite th

01 October 2024 1 mins read

Ipsen Achieves Its Record-High Score in 2024 S&P Global CSA, Setting New Company Benchmark 

We are proud to announce that Ipsen’s rating has reached an all-time high in the 2024 S&P Global Corporate Sustainability Assessment (CSA). Our score has increased by 4 points, from 57 in 2023 to 61 as od 19 September 2024, placing Ipsen in the 94th percentile of our industry. This remarkable achiev

23 September 2024 1 mins read

Ipsen’s Commitment to Zero Emissions: A Step Towards a Sustainable Future 

Zero Emission Day is a global initiative that raises awareness about the impact of human activities on climate change and promotes sustainable practices. 

12 September 2024 4 mins read

Partnering for Progress: The Importance of Collaboration in Primary Biliary Cholangitis (PBC) Awareness  

September is a month dedicated to raising awareness about Primary Biliary Cholangitis, I find myself reflecting on the challenges faced by those living with rare cholestatic disease. PBC Awareness Day on September 10th is not just a date on the calendar; it’s a reminder that understanding and suppor